All preclinical studies displayed noticeable uptake in EGFR-sensitive tumors in mice with NSCLC xenograft models, and this uptake can be effectively blocked by the cold erlotinib, suggesting the specifically saturable binding of this tracer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.